VRTX · 10-Q · 2026Q3 · Full report
Guidance / Outlook
VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 23 · Surprise 24 · In source text
Vertex expects to complete enrollment in both Phase 3 trials of suzetrigine for diabetic peripheral neuropathy by the end of 2026 and share results in mid-2027. It expects to complete enrollment in the Phase 3 atumelnant trial in adults with congenital adrenal hyperplasia in the first quarter of 2027, and to advance VX-017 into pivotal development in 2027. Vertex also expects to launch PALSONIFY in European markets in the second half of 2027 and states that its existing cash, current marketable securities, and operating cash flows are expected to fund operations for at least the next twelve months.
Key facts
- Vertex decided to focus on accelerating VX-017 development, which has potential to reach more people than zimislecel, and expects to advance VX-017 into pivotal development in 2027. source
- Vertex expects to complete enrollment in both Phase 3 suzetrigine trials in diabetic peripheral neuropathy by the end of 2026 and expects to share results in mid-2027. source
- Vertex expects to conduct a pre-planned interim analysis of inaxaplin for potential U.S. accelerated approval after the interim-analysis cohort has been treated for 48 weeks and to share the data in early 2027. source
- Vertex expects to complete enrollment in its 150-person, global, 32-week Phase 3 trial of atumelnant in adults with congenital adrenal hyperplasia in the first quarter of 2027. source
- PALSONIFY was approved in the European Union in April 2026; Vertex expects to begin launches in European markets in the second half of 2027. source
- Vertex initiated a Phase 2/3 clinical trial evaluating atumelnant in people with ACTH-dependent Cushing’s syndrome. source
- Vertex is enrolling and dosing patients in the Phase 3 portion of the OLYMPUS Phase 2/3 pivotal trial of povetacicept in people with primary membranous nephropathy. source
- Vertex completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin for APOL1-mediated kidney disease. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | Vertex decided to focus on accelerating VX-017 development, which has potential to reach more people than zimislecel, and expects to… |